• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Editorial Staff
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter Telegram
Iranian Journal of Biotechnology
Articles in Press
Current Issue
Journal Archive
Volume Volume 16 (2018)
Volume Volume 15 (2017)
Issue Issue 4
Issue Issue 3
Issue Special Issue (Abstract Book)
Issue Issue 2
Issue Issue 1
Volume Volume 14 (2016)
Volume Volume 13 (2015)
Volume Volume 12 (2014)
Volume Volume 11 (2013)
Volume Volume 10 (2012)
Volume Volume 9 (2011)
Volume Volume 8 (2010)
Volume Volume 7 (2009)
Volume Volume 6 (2008)
Volume Volume 5 (2007)
Volume Volume 4 (2006)
Volume Volume 3 (2005)
Volume Volume 2 (2004)
Volume Volume 1 (2003)
Aissaoui, S., Ouled-Haddar, H., Sifour, M., Beggah, C., Benhamada, F. (2017). Biological Removal of the Mixed Pharmaceuticals: Diclofenac, Ibuprofen, and Sulfamethoxazole Using a Bacterial Consortium. Iranian Journal of Biotechnology, 15(2), 135-142. doi: DOI:10.15171/ijb.1530
Salima Aissaoui; Houria Ouled-Haddar; Mohamed Sifour; Cherifa Beggah; Farida Benhamada. "Biological Removal of the Mixed Pharmaceuticals: Diclofenac, Ibuprofen, and Sulfamethoxazole Using a Bacterial Consortium". Iranian Journal of Biotechnology, 15, 2, 2017, 135-142. doi: DOI:10.15171/ijb.1530
Aissaoui, S., Ouled-Haddar, H., Sifour, M., Beggah, C., Benhamada, F. (2017). 'Biological Removal of the Mixed Pharmaceuticals: Diclofenac, Ibuprofen, and Sulfamethoxazole Using a Bacterial Consortium', Iranian Journal of Biotechnology, 15(2), pp. 135-142. doi: DOI:10.15171/ijb.1530
Aissaoui, S., Ouled-Haddar, H., Sifour, M., Beggah, C., Benhamada, F. Biological Removal of the Mixed Pharmaceuticals: Diclofenac, Ibuprofen, and Sulfamethoxazole Using a Bacterial Consortium. Iranian Journal of Biotechnology, 2017; 15(2): 135-142. doi: DOI:10.15171/ijb.1530

Biological Removal of the Mixed Pharmaceuticals: Diclofenac, Ibuprofen, and Sulfamethoxazole Using a Bacterial Consortium

Article 8, Volume 15, Issue 2 - Serial Number 57, Spring 2017, Page 135-142  XML PDF (248 K)
Document Type: Research Paper
DOI: DOI:10.15171/ijb.1530
Authors
Salima Aissaoui1; Houria Ouled-Haddar1; Mohamed Sifour 1; Cherifa Beggah2; Farida Benhamada2
11Laboratory of Molecular Toxicology, Faculty of Nature and life Sciences, University of Mohammed Seddik Benyahia - Jijel, 98 Ouled Aissa-Jijel 1800-Algeria, Algeria
2Department of Applied Microbiology and Food Sciences, Faculty of Nature and Life Sciences, University of Mohammed Seddik Benyahia- Jijel, 98 Ouled Aissa-Jijel 1800-Algeria, Algeria
Abstract
Background: The presence of pharmaceuticals at low concentrations (ng to μg) in the environment has become a hot spot for researchers in the past decades due to the unknown environmental impact and the possible damages they might have to the plantae and fauna present in the aquatic systems, as well as to the other living organisms.
Objectives: The aim of the present investigation was to develop a bacterial consortium isolated from diff erent origins to evaluate the ability of such a consortium to remove a mixture of pharmaceuticals in the batch system at lab scale, as well as assessment of its resistance to the other micropollutants present in the environment.
Material and Methods: Using a closed bottle test, biodegradation of the mixed pharmaceuticals including Diclofenac (DCF), Ibuprofen (IBU), and Sulfamethoxazole (SMX) (at a concentration of 3 mg.L-1 of each drug) by the bacerial consortium was investigated. The test was carried out under metabolic (pharmaceutical was used as the sole source of carbon) and co-metabolic condition (in the presence of glucose). Finally, the ability of the bacterial consortium to resist other micropollutants like antibiotics and heavy metals was investigated.
Results: Under the metabolic condition, the mixed bacteria (i.e., consortium) were able to metabolize 23.08% and 9.12% of IBU, and DCF at a concentration of 3 mg.L-1 of each drug, respectively. Whereas, in co-metabolic conditions, IBU was eliminated totally, in addition, 56% of the total concentration of DCF was removed, as well. In both metabolic and cometabolic conditions, removal of SMX was not observed. The selected bacteria were able to resist to most of the applied antibiotics and the used heavy metals, except mercury, where only one strain (S4) was resistant to the later heavy metal.
Conclusion: Results suggest that the developed consortium might be an excellent candidate for the application in the
bioremediation process for treating ecosystems contaminated with the pharmaceutical.
Keywords
Bacterial consortium; Biodegradation; Co-metabolism; Mixed pharmaceutical
Main Subjects
Environmental Biotechnology
Statistics
Article View: 358
PDF Download: 41
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by sinaweb.